FDA Accepts Resubmission of Supplemental Biologics License Application for Dupixent for Chronic Spontaneous Urticaria in Patients Under 12

Your email address will not be published. Required fields are marked *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Comment *